Ratio Therapeutics has successfully dosed the first cohort in its Phase 1/2 study evaluating a novel FAP-targeted radiopharmaceutical in patients with late-stage aggressive sarcomas

BOSTON, MA, December 16, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that dosing of the first cohort has been completed in the ATLAS trial, a Phase […] The post Ratio Therapeutics has successfully dosed the first cohort in its Phase 1/2 study evaluating a novel FAP-targeted radiopharmaceutical in patients with late-stage aggressive sarcomas first appeared on Ratio Therapeutics .